Company news

Vaxcyte, Inc. news in 2026

Vaxcyte, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

October 9, 2026

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

October 6, 2026

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

October 5, 2026

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

October 5, 2026

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

October 5, 2026

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

October 4, 2026

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

September 3, 2026

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026

Vaxcyte to Participate in Upcoming Investor Conferences

July 8, 2026

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

June 2, 2026

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

April 6, 2026

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

March 22, 2026

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

March 17, 2026

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 24, 2026

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

February 11, 2026

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

February 10, 2026

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

February 5, 2026

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 2, 2026

Vaxcyte Announces Pricing of $550 Million Public Offering

January 29, 2026

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 29, 2026

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

January 21, 2026

Calls in 2026

Decks in 2026